Asgard Therapeutics

About Asgard Therapeutics

Asgard Therapeutics is a Swedish private biotech company focused on developing groundbreaking cancer immunotherapies through direct cell reprogramming technologies. As a spin-off from Lund University, they are pioneering gene therapy approaches with their lead program AT-108, an off-the-shelf gene therapy designed to trigger immune responses via professional antigen-presenting cells, overcoming logistical and manufacturing challenges of conventional cell-based therapies.

Products & Services

AT-108:A proprietary lead program designed as an off-the-shelf gene therapy to initiate immune responses for cancer immunotherapy using the properties of professional antigen-presenting cells.

Specialties

Direct Cell Reprogramming Cancer Immunotherapy Gene Therapy Immuno-oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 30000000 MR: - FA: €30 million FAN: 30000000	D: 2024-03-14 FD: 2024-03-14	5 investors
2	RT: Series A T: - FT: Series A	A: 32400000 MR: - FA: €30M FAN: 32400000	D: 2024-03-14 FD: 2024-03-14	5 investors

Series A Latest

2024-03-14

$30.0M

5 investors (Pro only)

Series A 2024-03-14

$32.4M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Cristiana Pires

Co-founder and CEO

LinkedIn (Pro only)

S

Shane Olwill

Chief Development Officer

LinkedIn (Pro only)

F

Fábio Rosa

PhD, Co-founder and Head of Research

F

Filipe Pereira

PhD, Co-founder and Head of Innovation

J

Jan Villadsen

Head of Finance

F

Frank Hennecke

Head of CMC

View 19 more team members with Pro

Unlock Full Team Directory

Recent News